[
  {
    "ts": null,
    "headline": "Regeneron to Report Q1 Earnings: What's in Store for the Stock?",
    "summary": "Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports first-quarter results on April 29.",
    "url": "https://finnhub.io/api/news?id=5d6177252cf6a3a2acf093e53796b36b30d84114fa6c4fa8fc271ee470e70e5c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745346540,
      "headline": "Regeneron to Report Q1 Earnings: What's in Store for the Stock?",
      "id": 134039244,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports first-quarter results on April 29.",
      "url": "https://finnhub.io/api/news?id=5d6177252cf6a3a2acf093e53796b36b30d84114fa6c4fa8fc271ee470e70e5c"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals (NasdaqGS:REGN) Expands U.S. Capacity With US$3 Billion Fujifilm Partnership",
    "summary": "Regeneron Pharmaceuticals (NasdaqGS:REGN) announced a major expansion of its manufacturing capacity, including a $3 billion deal with Fujifilm Diosynth Biotechnologies and further investments at its Tarrytown campus. This expansion underscores Regeneron's commitment to growth within the biopharmaceutical industry and aligns with recent FDA approvals for products like Dupixent. However, the company's share price decreased by 2% over the past week, a move that might have been driven by broader...",
    "url": "https://finnhub.io/api/news?id=42821bd531130fbea5bf5ce2309feca3a166032423c61c19d319b657164ccaa3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745342613,
      "headline": "Regeneron Pharmaceuticals (NasdaqGS:REGN) Expands U.S. Capacity With US$3 Billion Fujifilm Partnership",
      "id": 134039245,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals (NasdaqGS:REGN) announced a major expansion of its manufacturing capacity, including a $3 billion deal with Fujifilm Diosynth Biotechnologies and further investments at its Tarrytown campus. This expansion underscores Regeneron's commitment to growth within the biopharmaceutical industry and aligns with recent FDA approvals for products like Dupixent. However, the company's share price decreased by 2% over the past week, a move that might have been driven by broader...",
      "url": "https://finnhub.io/api/news?id=42821bd531130fbea5bf5ce2309feca3a166032423c61c19d319b657164ccaa3"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly, Vertex, AbbVie, and More Pharma Stocks to Own as Tariffs Loom",
    "summary": "President Donald Trump’s tariff policy is the latest blow to a pharmaceutical sector already facing mounting uncertainties, including how Robert F. Kennedy Jr., secretary of Health and Human Services, will change the U.S. healthcare system.  While pharmaceuticals have so far been spared from import taxes, Trump has vowed to impose a “major” tariff on the sector “very shortly.”  A 25% tariff could reduce earnings in the sector by about 15%, Jefferies analyst Akash Tewari noted last week, but mitigation efforts such as stockpiling, increasing drug prices or shifting manufacturing to the U.S. could reduce the damage to the mid single digits.",
    "url": "https://finnhub.io/api/news?id=bb87f87fa47de290d5a66e6b72d3829b49f8e309d26fc95a8a2d94592ea90561",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745334780,
      "headline": "Eli Lilly, Vertex, AbbVie, and More Pharma Stocks to Own as Tariffs Loom",
      "id": 134038508,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "President Donald Trump’s tariff policy is the latest blow to a pharmaceutical sector already facing mounting uncertainties, including how Robert F. Kennedy Jr., secretary of Health and Human Services, will change the U.S. healthcare system.  While pharmaceuticals have so far been spared from import taxes, Trump has vowed to impose a “major” tariff on the sector “very shortly.”  A 25% tariff could reduce earnings in the sector by about 15%, Jefferies analyst Akash Tewari noted last week, but mitigation efforts such as stockpiling, increasing drug prices or shifting manufacturing to the U.S. could reduce the damage to the mid single digits.",
      "url": "https://finnhub.io/api/news?id=bb87f87fa47de290d5a66e6b72d3829b49f8e309d26fc95a8a2d94592ea90561"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron partners with Fujifilm to broaden manufacturing capacity",
    "summary": "Regeneron is currently expanding its Tarrytown campus with an investment of nearly $3.6bn.",
    "url": "https://finnhub.io/api/news?id=ad03cb387309776252bd10c32ac55b8e265fd78d72f718059fd52e69760a5fe9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745331932,
      "headline": "Regeneron partners with Fujifilm to broaden manufacturing capacity",
      "id": 134039247,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron is currently expanding its Tarrytown campus with an investment of nearly $3.6bn.",
      "url": "https://finnhub.io/api/news?id=ad03cb387309776252bd10c32ac55b8e265fd78d72f718059fd52e69760a5fe9"
    }
  },
  {
    "ts": null,
    "headline": "Analysts Estimate Regeneron (REGN) to Report a Decline in Earnings: What to Look Out for",
    "summary": "Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=7ac4693fb49cc0efd52d2f6d05203d331877dfdb4fba5cc14237eb63313e7e59",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745330468,
      "headline": "Analysts Estimate Regeneron (REGN) to Report a Decline in Earnings: What to Look Out for",
      "id": 134039248,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=7ac4693fb49cc0efd52d2f6d05203d331877dfdb4fba5cc14237eb63313e7e59"
    }
  },
  {
    "ts": null,
    "headline": "Drug Companies Step Up 'Make in America' Plans to Counter Tariffs",
    "summary": "Drugmakers Roche and Regeneron said they will spend billions of dollars to expand U.S. manufacturing, the latest pharmaceutical companies to commit to American production as new and future tariffs loom over medicines made abroad.  Regeneron, which makes drugs for skin and respiratory diseases, is doubling its U.S. manufacturing capacity in a new $3 billion, 10-year agreement with Fujifilm Diosynth Biotechnologies.  Fujifilm’s plant in Holly Springs, N.C., will make bulk drug material for Regeneron medicines.",
    "url": "https://finnhub.io/api/news?id=6d84594899f153fb2ab5d6aff1f8fe03030cfa7637c351c4935e1362e88fdf3f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745319084,
      "headline": "Drug Companies Step Up 'Make in America' Plans to Counter Tariffs",
      "id": 134039249,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Drugmakers Roche and Regeneron said they will spend billions of dollars to expand U.S. manufacturing, the latest pharmaceutical companies to commit to American production as new and future tariffs loom over medicines made abroad.  Regeneron, which makes drugs for skin and respiratory diseases, is doubling its U.S. manufacturing capacity in a new $3 billion, 10-year agreement with Fujifilm Diosynth Biotechnologies.  Fujifilm’s plant in Holly Springs, N.C., will make bulk drug material for Regeneron medicines.",
      "url": "https://finnhub.io/api/news?id=6d84594899f153fb2ab5d6aff1f8fe03030cfa7637c351c4935e1362e88fdf3f"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron signs $3 billion deal with contract drugmaker to boost US manufacturing",
    "summary": "Major U.S. drugmakers, including Eli Lilly  and Johnson & Johnson , have announced additional investments in their U.S. production as they grapple with the threat of drug import duties from President Donald Trump's administration.  Regeneron said the deal would nearly double its U.S. manufacturing capability, adding that an expansion of about $3.6 billion of its Tarrytown, New York-based facility is also underway.  Tokyo-based Fujifilm Diosynth, under the terms of the deal, will manufacture and supply drug products for Regeneron's biologic medicines for a span of 10 years at its North Carolina-based facility, which is set to be operational later this year.",
    "url": "https://finnhub.io/api/news?id=24514eab06a21a0643c13f62955a097363feed29d7905dd1cd9647edad6641fe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745317011,
      "headline": "Regeneron signs $3 billion deal with contract drugmaker to boost US manufacturing",
      "id": 134032066,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Major U.S. drugmakers, including Eli Lilly  and Johnson & Johnson , have announced additional investments in their U.S. production as they grapple with the threat of drug import duties from President Donald Trump's administration.  Regeneron said the deal would nearly double its U.S. manufacturing capability, adding that an expansion of about $3.6 billion of its Tarrytown, New York-based facility is also underway.  Tokyo-based Fujifilm Diosynth, under the terms of the deal, will manufacture and supply drug products for Regeneron's biologic medicines for a span of 10 years at its North Carolina-based facility, which is set to be operational later this year.",
      "url": "https://finnhub.io/api/news?id=24514eab06a21a0643c13f62955a097363feed29d7905dd1cd9647edad6641fe"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines",
    "summary": "New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron’s biologic medicines and support high-paying jobs in the region Regeneron’s ongoing and planned investments in New York and North Carolina infrastructure and manufacturing expected to total more than $7 billion TARRYTOWN, N.Y., April 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a significant expansion of its",
    "url": "https://finnhub.io/api/news?id=ac7102491b433575638d00c8be538efd40ebad1c577270d7dc31de9364c97b7b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745316000,
      "headline": "Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines",
      "id": 134032067,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron’s biologic medicines and support high-paying jobs in the region Regeneron’s ongoing and planned investments in New York and North Carolina infrastructure and manufacturing expected to total more than $7 billion TARRYTOWN, N.Y., April 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a significant expansion of its",
      "url": "https://finnhub.io/api/news?id=ac7102491b433575638d00c8be538efd40ebad1c577270d7dc31de9364c97b7b"
    }
  },
  {
    "ts": null,
    "headline": "Celldex Therapeutics: Strong Pipeline But Uncertainties Remain",
    "summary": "Celldex Therapeutics: Strong Pipeline But Uncertainties Remain",
    "url": "https://finnhub.io/api/news?id=86d41e896994b5a6991acd7c35e1ad930214df3a07b4d63cfe849368b7cbc0dd",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745307622,
      "headline": "Celldex Therapeutics: Strong Pipeline But Uncertainties Remain",
      "id": 134032095,
      "image": "",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=86d41e896994b5a6991acd7c35e1ad930214df3a07b4d63cfe849368b7cbc0dd"
    }
  }
]